Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones.

--Prime Medicine, Inc. today announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex vivo T-cell therapies.

Bristol Myers Squibb is turning to the prime-editing technology of Prime Medicines for the R&D of new cell therapies for cancer and immunology. The pharma giant is paying $110 million up front to ...

Bristol Myers Squibb will handle development, manufacturing and commercialization of the T-cell therapies. Prime Medicine will provide support for gene editing strategy and reagent development.

Prime Medicine has partnered with Bristol Myers Squibb to develop ex vivo T-cell therapies. BMS will pay $55 million up front and invest another $55 million, but the partnership could be worth ...

Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb (NYSE:BMY), which includes a $55M equity investment. Under the deal ...

Prime Medicine, founded with gene ... At the same, it announced a new cell therapy pact with Bristol Myers Squibb that will immediately bring in $110 million, plus far more in potential milestones.

Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies ...

On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next ...

Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies ...

Collaboration Combines Prime Medicine's Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb's Broad Expertise in Development and Commercialization of Novel Cell Therapies Prime ...